Eli Lilly (LLY) analyst actions

Rating and price-target actions on LLY in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the LLY overview →

8 measured LLY analyst action events.

DateHeadlineEvent5-minTo close
Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trialsPress release-0.16%+1.97%
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweightPress release-0.45%-1.14%
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweightPress release+0.27%+0.07%
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trialPress release+2.41%+1.45%
Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweightPress release+0.40%+1.02%
Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeksPress release+0.10%-2.30%
Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweightPress release+1.61%+1.93%
FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical ProblemsPress release+0.11%+3.08%
Get an email when LLY moves on news →
Keep exploring

More LLY: earnings → · SEC filings → · LLY overview →

Other Health Care names and their analyst actions

TickerEventsMedian 30-min% positive
Johnson & Johnson (JNJ)2,000++0.06%56%
UnitedHealth Group (UNH)2,000+-0.03%48%

Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.